Economic benefits of aggressive lipid lowering: A managed care perspective

American Journal of Managed Care

Volumn 4, Issue 1, 1998, Pages 65-74

  McKenney, James M ^a   Kinosian, Bruce ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN;

ARTICLE; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; HEALTH CARE COST; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; MANAGED CARE; MANAGED CARE ORGANIZATION; MORTALITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLINICAL TRIALS; CORONARY DISEASE; COST-BENEFIT ANALYSIS; DISEASE MANAGEMENT; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; HYPERLIPIDEMIAS; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY-ADJUSTED LIFE YEARS; UNITED STATES; VALUE OF LIFE;

EID: 0031879172     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. American Heart Association. Heart and stroke facts: 1996 statistical supplement. Dallas, TX: American Heart Association; 1996.
2. National Center for Health Statistics. Health, United States, 1995. Hyattsville, MA: Public Health Service; 1996.
3. Every NR, Parsons LS, Hlatky M, Martin JS, Weaver WD. A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction. N Engl J Med 1996;335:1253-1260.
4. Weintraub WS, Mauldin PD, Becker E, Kosinski AS, King SB. A comparison of the costs of and quality of life after coronary angioplasty or coronary surgery for multivessel coronary artery disease. Results from the Emory Angioplasty Versus Surgery Trial (EAST). Circulation 1995;92:2831-2840.
5. Sempos CT, Cleeman JI, Carroll MD, et al. Prevalence of high blood cholesterol among US adults. An update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel. JAMA 1993; 269:3009-3014.
6. DeBusk RF, Miller NH, Superko RH, et al. A case-management system for coronary risk factor modification after acute myocardial infarction. Ann Intern Med 1994;120: 721-729.
7. Allen JK, Blumenthal RS. Coronary risk factors in women six months after coronary artery bypass grafting. Am J Cardiol 1995;75:1092-1095.
8. Cohen MV, Byrne MJ, Levine B, Gutowski T, Adelson R. Low rate of treatment of hypercholesterolemia by cardiologists in patients with suspected and proven coronary artery disease. Circulation 1991;83:1294-1304.
9. Schectman JM, Elinsky EG, Bartman BA. Primary care clinician compliance with cholesterol treatment guidelines. J Gen Intern Med 1991;6:121-5.
10. National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994;89:1329-1445.
11. Yusuf S, Anand S. Cost of prevention. The case of lipid lowering. Circulation 1996;93:1774-6.
12. Superko HR. Failure of cholesterol treatment in patients with coronary artery disease: A cost-effective solution. Am J Cardiol 1995;75:277.
13. Siegel PZ, Waller MN, Frazier EL, Mariolis P. Behavioral Risk Factor Surveillance System: Summary of data for 1991. MMWR CDC Surveill Summ 1993;42:23-30.
14. Caggiula AW, Watson JE, Kuller LH, et al. Cholesterol-lowering intervention program. Effect of the Step I diet in community office practices. Arch Intern Med 1996;156: 1205-1213.
15. Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust 1996;164:208-211.
16. Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: Factors limiting achievement of lipid goals. Am J Med 1996;100: 197-204.
17. Downey NA, Lee E, Sampsel JM, Sikand G, Kashyap ML, Hager JM. Undertreatment of dsylipidemia in veterans with coronary artery disease. Followup after NCEP:ATP II J Am Coll Cardiol 1996;27:304A. Abstract.
18. Heudebert GR, Van Ruiswyk J, Hiatt J, Schectman G. Combination drug therapy for hypercholesterolemia. The trade-off between cost and simplicity. Arch Intern Med 1993;153:1828-1837.
19. Oster G, Borok GM, Menzin J, et al. Cholesterol-reduction intervention study (CRIS): A randomized trial to assess effectiveness and costs in clinical practice. Arch Intern Med 1996;156:731-739.
20. Shaffer J, Wexler LF. Reducing low-density lipoprotein cholesterol in an ambulatory care system: Results of a multidisciplinary collaborative practice lipid clinic compared with traditional physician-based care. Arch Intern Med 1995;155: 2330-2335.
21. Schectman G, Wolff N, Byrd JC, Hiatt JG, Hartz A. Physician extenders for cost-effective management of hypercholesterolemia. J Gen Intern Med 1996;11:277-286.
22. Shepard J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307.
23. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
24. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335:1001-1009.
25. Reckless JPD. The 45 Study and its pharmacoeconomic implications. PharmacoEconomics 1996;9:101-105.
26. Pederson TR, Kjekshus J, Boccuzzi SJ, Epstein RS. Clinical and resource utilization benefits of the Scandinavian Simvastatin Survival Study (4S) applied to the US population. Circulation 1995; 92 (suppl):I-521. Abstract.
27. Pedersen TR, Kjekshus J, Berg K, et al. Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. Circulation 1996;93:1796-1802.
28. Kinosian B, Glick H, Schwartz SJ. Scandinavian Simvastatin Survival Study (45): Cost-effectiveness (CE) of cholesterol lowering treatment. J Am Coll Cardiol 1996; 27:165A. Abstract.
29. Schwartz JS, Kjekshus J, Pedersen TR. Impact of cholesterol lowering on resource use and cost among patients with coronary heart disease (CHD): Results from 45. Circulation 1995;92 (suppl):I-510. Abstract.
30. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995; 15:678-682.
31. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987;317:1237-1245.
32. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol-lowering. JAMA 1984;251:365-374.
33. West of Scotland Coronary Prevention Group. West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 1996;348:1339-1342.
34. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (45). Lancet 1995;345:1274-1275.
35. Braunwald E, Pfeffer M, Sacks F. CARE Trial results. Reported at the American College of Cardiology 45th Annual Scientific Session, Orlando, FL, March 24-26, 1996.
36. Alderman EL, Bourassa MG, Cohen LS, et al. Ten-year follow-up of survival and myocardial infarction in the randomized coronary artery surgery study. Circulation 1990;82:1629-1646.
37. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996;348:1079-1082.
38. Ambrose JA, Tannenbaum MA, Alexopoulos D, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 1988;12:56-62.
39. Little WC, Constantinescu M, Applegate RJ, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation 1988;78:1157-1166.
40. Campeau L, Enjalbert M, Lesperance J, et al. The relation of risk factors to the development of arteriosclerosis in saphenous-vein bypass grafts and the progression of disease in the native circulation. N Engl J Med 1984;311:1329-1332.
41. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997;336:153-162.
42. Gordon DJ. Cholesterol lowering reduces mortality: Rresults of updated meta-analysis. Circulation 1996;94 (suppl):I-579. Abstract.
43. Goodman L, Garber AM, Grover SA, Hlatky MA. Task Force 6. Cost effectiveness of assessment and management of risk factors. J Am Coll Cardiol 1996;27:1020-1030.
44. Tengs TO, Adams ME, Pliskin JS, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk: Anal 1995;15:369-390.
45. Gaspoz JM, Goldman P, Williams L, Weinstein M, Goldman L. Cost-effectiveness of aspirin in secondary prevention of coronary heart disease. Circulation 1995;92 (suppl):I-47. Abstract.
46. Fiscella K, Franks P. Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling. JAMA 1996;275:1247-1251.
47. Kinosian BP, Eisenberg JM. Cutting into cholesterol. Cost-effective alternatives for treating hypercholesterolemia. JAMA 1988;259:2249-2254.
48. Oster C, Epstein AM. Cost-effectiveness of antihyperlipemic therapy in the prevention of coronary heart disease. The case of cholestyramine. JAMA 1987;258:2381-2387.
49. Schulman KA, Kinosian B, Jacobson TA, et al. Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management. JAMA 1990;264:3025-33.
50. Hilleman DE, Pincus KT, Wadibia EC, Stading JA, Woodruff MP, Lucas BD. Comparative cost-effectiveness of bile acid sequestering resins, HMG Co-A reductase inhibitors, and their combination in patients with hypercholesterolemia. J Man Care Pharm 1995;1:188-192.
51. Goldman L, Weinstein MC, Goldman PA, Williams LW. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 1991;265:1145-1151.
52. Tosteson ANA, Weinstein MC, Hunink MGM, et al. Cost effectiveness of populationwide educational approaches to reduce serum cholesterol levels. Circulation 1997;95: 24-30.
53. Johannesson M, Jönsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997;336:332-336.
54. Rivière M, Wang S, Leclerc C, Fitzsimon C, Tretiak R. Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada. Can Med Assoc J 1997;156:991-997.
55. Ashraf T, Hay JW, Pitt B, et al. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol 1996;78:409-414.
56. American Heart Association. 1997 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association, 1997.
57. Shalowitz M, Heaton AH. Cost effectiveness of risk reduction: The managed care perspective. Am J Med 1996; 101 (suppl 4A):71S-75S.
58. Hamilton VH, Racicot FE, Zowall H, Coupal L, Grover SA. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C. JAMA 1995;273:1032-1038.